Efficacy of COX-2 inhibitors in a case of congenital nephrogenic diabetes insipidus

Pediatric Nephrology

Volumn 20, Issue 12, 2005, Pages 1814-1817

  Soylu, Alper ^a   Kasap, Belde ^a   Öǧün, Nilüfer ^a   Õztürk, Yeçim ^a   Türkmen, Mehmet ^a   Hoefsloot, Lies ^b   Kavukçu, Salih ^c  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c NONE   (Turkey)

Author keywords

Amiloride; Cyclooxygenase 2inhibitors; Hydrochlorothiazide; Nephrogenic diabetes insipidus

Indexed keywords

AMILORIDE PLUS HYDROCHLOROTHIAZIDE; ARGIPRESSIN; ARGIPRESSIN RECEPTOR; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; IBUPROFEN; INDOMETACIN; ROFECOXIB;

ARTICLE; CASE REPORT; DIURESIS; DRUG EFFICACY; DRUG SUBSTITUTION; FAILURE TO THRIVE; GENE MUTATION; GENETIC ANALYSIS; HUMAN; MALE; NEPHROGENIC DIABETES INSIPIDUS; OUTCOMES RESEARCH; POLYURIA; PRESCHOOL CHILD; PRIORITY JOURNAL; SIDE EFFECT; SODIUM RESTRICTION; VOMITING; WATER LOSS;

AMILORIDE; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DIABETES INSIPIDUS, NEPHROGENIC; DIURETICS; DNA MUTATIONAL ANALYSIS; FOLLOW-UP STUDIES; GENETIC DISEASES, X-LINKED; HUMANS; HYDROCHLOROTHIAZIDE; INFANT; LACTONES; MALE; RECEPTORS, VASOPRESSIN; SULFONES; TIME FACTORS; TREATMENT OUTCOME;

EID: 28444485287     PISSN: 0931041X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00467-005-2057-8     Document Type: Article

References (20)

1. Sasaki S (2004) Nephrogenic diabetes insipidus: Update of genetic and clinical aspects. Nephrol Dial Transplant 19:1351-1353 10.1093/ndt/gfh172
2. Knoers NVAM, Monnens LAH (2004) Nephrogenic diabetes insipidus. In: Avner ED, Harmon WE, Niaudet P (eds) Pediatric Nephrology, 5th edn. Lippincott, Philadelphia, pp 777-787
3. Wildin RS, Cogdell DE (1999). Clinical utility of direct mutation testing for congenital nephrogenic diabetes insipidus in families. Pediatrics 103:632-639 10.1542/peds.103.3.632
4. Dell K, MacRae, Avner DA (2004) Nephrogenic diabetes insipidus. In: Behrman RE, Kliegman RM, Jenson HB (eds) Nelson textbook of pediatrics, 17th edn. Elsevier, Philadelphia, pp 1762-1763
5. Vargas PR, Forestier L, Niaudet P (1997) Mutations in the vasopressin V2 receptor and aquaporin-2 genes in 12 families with congenital nephrogenic diabetes insipidus. J Am Soc Nephrol 8:1855-1862 9402087
6. Janjua NR, Jonassen TEN, Langhoff S, Thomsen K, Christensen S (2001) Role of sodium depletion in acute antidiuretic effect of bendroflumethiazide in rats with nephrogenic diabetes insipidus. J Pharmacol Exp Ther 299:307-313 11561093
7. Magaldi AJ (2000) New insights into the paradoxical effect of thiazides in diabetes insipidus therapy. Nephrol Dial Transplant 15:1903-1905 10.1093/ndt/15.12.1903
8. Kim GH, Lee JW, Oh YK, Chang HR, Joo KW, Na KY, Earm JH, Knepper MA, Han JS (2004) Antidiuretic effect of hydrochlorothiazide in lithium-induced nephrogenic diabetes insipidus is associated with upregulation of aquaporin-2, Na-Cl cotransporter, and epithelial sodium channel. J Am Soc Nephrol 15:2836-2843 10.1097/01.ASN.0000143476.93376.04
9. Kirchlechner V, Koller DY, Seidl R (1999) Treatment of nephrogenic diabetes insipidus with hydrochlorothiazide and amiloride. Arch Dis Child 80:548-552 10332005
10. Rascher W, Rosendahl W, Henrichs IA, Maier R, Seyberth HR (1987) Congenital nephrogenic diabetes insipidus: Vasopressin and prostaglandin in response to treatment with hydrochlorothiazide and indomethacin. Pediatr Nephrol 1:485-490 10.1007/BF00849258
11. Handler JS (1981) Vasopressin-prostaglandin interactions in the regulation of epithelial cells' permeability to water. Kidney Int 19:831-838 6267350
12. Scharschmidt LA, Dunn MJ (1983) Prostaglandin synthesis by rat glomerular mesangial cells in culture. Effects of angiotensin II and arginine vasopressin. J Clin Invest 71:1756-1764 6408123
13. Hochberg Z, Even L, Danon A (1998) Amelioration of polyuria in nephrogenic diabetes insipidus due to aquaporin-2 deficiency. Clin Endocrinol (Oxf) 49:39-44
14. Stoff JS, Rosa RM, Silva P, Epstein FH (1981) Indomethacin impairs water diuresis in the DI rat: Role of prostaglandins independent of ADH. Am J Physiol 241:F231-F237 6945054
15. Kim SW, Kim JW, Choi KC, Ma SK, Oh Y, Jung JY, Kim J, Lee J (2004) Indomethacin enhances shuttling of aquaporin-2 despite decreased abundance in rat kidney. J Am Soc Nephrol 15:2998-3005 10.1097/ 01.ASN.0000145877.28811.82
16. Pattaragarn A, Alon US (2003) Treatment of congenital nephrogenic diabetes insipidus by hydrochlorothiazide and cyclooxygenase-2 inhibitor. Pediatr Nephrol 18:1073-1076 10.1007/s00467-003-1195-0
17. Gross JM, Dwyer JE, Knox FG (1999) Natriuretic response to increased pressure is preserved with COX-2 inhibitors. Hypertension 34:1163-1167 10567199
18. DeMaria AN, Weir MR (2003) Coxibs - beyond the GI tract: Renal and cardiovascular issues. J Pain Symptom Manage 25 [Suppl 2]: S41-S49
19. Libber S, Harrison H, Spector D (1986) Treatment of nephrogenic diabetes insipidus with prostaglandin synthesis inhibitors. J Pediatr 108:305-311 3080575
20. Hooper L, Brown TJ, Elliott R, Payne K, Roberts C, Symmons D (2004) The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: Systematic review. BMJ 329:948-952 10.1136/bmj.38232.680567.EB